Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A pharmacy benefit manager perspective.

J R Teagarden1, R S Epstein

  • 1Merck-Medco Managed Care, LLC, Montvale, NJ, USA.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combating acne.

Postgraduate medicine·2016
Same author

From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.

Clinical pharmacology and therapeutics·2015
Same author

Mobile medical applications: old wine in new bottles?

Clinical pharmacology and therapeutics·2014
Same author

Pharmacy benefit managers and their obligations during serious prescription drug shortages.

Clinical pharmacology and therapeutics·2013
Same author

The many sides of off-label prescribing.

Clinical pharmacology and therapeutics·2012
Same author

Influence of pharmacy benefit practices on off-label dispensing of drugs in the United States.

Clinical pharmacology and therapeutics·2012
Same journal

Development and Validation of a Brief Healthcare Insecurity Scale in a Sample of U.S. Adults Living with and without HIV.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

A Competency Framework for Health Technology Assessment Expertise: Results from a Delphi Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Physician-led Switching from Reference Biologics to Biosimilars: What is the Effect on selected Health-Related Outcomes and Costs for IBD Patients in Germany?

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Interpreting the Economic Value of TPEx in Recurrent or Metastatic HNSCC: The Importance of Decision Context, Utility Timing, and Treatment Burden.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Development, use and psychometric properties of vision and hearing bolt-ons for EQ-5D-3L and EQ-5D-5L: a systematic review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
See all related articles

Lipid-lowering therapies represent a significant cost for payers, prompting attention from pharmacy benefit managers (PBMs). A standardized framework is needed to evaluate PBMs

Area of Science:

  • Health economics
  • Pharmacoeconomics
  • Health policy

Background:

  • Lipid-lowering therapies constitute a substantial portion of drug expenditures, approximately 7% per patient per month.
  • This significant cost makes lipid-lowering drugs a key focus for payers and pharmacy benefit managers (PBMs) aiming to control healthcare spending.
  • PBMs employ various strategies to influence the utilization of these medications for both clinical and financial objectives.

Purpose of the Study:

  • To identify the gap between market demands for value-based information on lipid therapies and existing pharmacoeconomic evaluations.
  • To highlight the limitations of current pharmacoeconomic analysis units in aligning with policy makers' conceptual frameworks.
  • To emphasize the necessity of a standardized quantitative measurement framework for evaluating PBM activities in lipid therapy management.

Related Experiment Videos

Main Methods:

  • Review of current pharmacoeconomic evaluation methodologies for lipid-lowering therapies.
  • Analysis of measurement units employed in existing studies.
  • Assessment of the alignment between current evaluation frameworks and policy maker requirements.

Main Results:

  • A discernible gap exists between the need for practical value assessment of lipid therapies and the current state of pharmacoeconomic research.
  • Existing pharmacoeconomic metrics for lipid therapy are often not intuitive or easily integrated into policy decision-making processes.
  • The lack of a universally accepted quantitative framework hinders the effective evaluation of pharmacy benefit manager interventions.

Conclusions:

  • Effective evaluation of pharmacy benefit manager strategies in lipid therapy requires a more intuitive and policy-maker-friendly quantitative framework.
  • Developing a standardized measurement system is crucial for accurately assessing the value and impact of lipid-lowering drug management programs.
  • Bridging the gap in pharmacoeconomic evaluation will enhance evidence-based decision-making for payers and policymakers in managing lipid-lowering therapy costs.